NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.25 0.00 (0.00 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$17.25
Today's Range$17.17 - $17.36
52-Week Range$14.59 - $25.96
Volume7.01 million shs
Average Volume10.41 million shs
Market Capitalization$17.54 billion
P/E Ratio6.16
Dividend YieldN/A
Beta1.46
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3926-7267

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.85 billion
Cash Flow$4.5878 per share
Book Value$15.53 per share

Profitability

Net Income$-2,150,000,000.00

Miscellaneous

Employees51,792
Outstanding Shares1,016,877,000
Market Cap$17.54 billion
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings data on Wednesday, February, 13th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.53. The company earned $4.56 billion during the quarter, compared to the consensus estimate of $4.52 billion. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. Teva Pharmaceutical Industries's revenue for the quarter was down 15.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.93 earnings per share. View Teva Pharmaceutical Industries' Earnings History.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY19 earnings guidance on Wednesday, February, 13th. The company provided earnings per share (EPS) guidance of $2.20-2.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.82. The company issued revenue guidance of $17.0-17.4 billion, compared to the consensus revenue estimate of $17.99 billion.Teva Pharmaceutical Industries also updated its FY 2019 guidance to $2.20-2.50 EPS.

What price target have analysts set for TEVA?

20 brokerages have issued 1-year target prices for Teva Pharmaceutical Industries' stock. Their predictions range from $12.00 to $30.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $22.0667 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.

What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 1 sell rating, 13 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
  • 1. According to Zacks Investment Research, "Teva is facing significant challenges in the form of accelerated generic competition for its blockbuster product Copaxone, new competition for other branded products, pricing erosion in the U.S. generics business and a massive debt load. Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and is reducing global workforce to revive growth. Though Teva is progressing well on these re-structuring activities and its financial position seems more stable than before, we believe the company has a long way to go before it gains stability and resumption of organic growth seems unlikely until 2020. Teva’s shares have underperformed the generic industry in the past six months. Estimates have remained stable ahead of Q4 earnings release. Teva has a positive record of earnings surprises. " (1/21/2019)
  • 2. Maxim Group analysts commented, "Teva reported 3Q18 with revenues of $4.53B vs. $4.55B consensus and beat on the bottom line with non-GAAP EPS of $0.68 vs. $0.55. The beat was driven by positive impacts from the ongoing restructuring strategy with a spend base reduction of $2B YTD compared to 2017 (excluding FX) and on track to reach $3B by YE19." (11/1/2018)
  • 3. Cantor Fitzgerald analysts commented, "We rate TEVA 12-month price target of $25. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (9/27/2018)
  • 4. Mizuho analysts commented, "We lowered 2018 estimates due to weaker but note that stronger Copaxone and EpiPen could make up the difference. We reiterate our Buy rating and $28 PT, but have become more cautious on a timely migraine approval on Sept 16. We see shares as undervalued even if approval is delayed." (8/24/2018)

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

News stories about TEVA stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 24,516,652 shares, a decrease of 34.6% from the January 15th total of 37,492,387 shares. Based on an average trading volume of 6,994,019 shares, the short-interest ratio is presently 3.5 days. Approximately 2.3% of the company's shares are sold short. View Teva Pharmaceutical Industries' Current Options Chain.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), Bank of America (BAC), Micron Technology (MU), Alibaba Group (BABA), Intel (INTC), Gilead Sciences (GILD), NVIDIA (NVDA), Cisco Systems (CSCO) and QUALCOMM (QCOM).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 48)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Brahman Capital Corp. (1.20%), Polaris Capital Management LLC (1.02%), Northern Trust Corp (0.66%), Harel Insurance Investments & Financial Services Ltd. (0.56%), Clal Insurance Enterprises Holdings Ltd (0.37%) and Menora Mivtachim Holdings LTD. (0.36%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Which major investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Eaton Vance Management, Acadian Asset Management LLC, Thornburg Investment Management Inc., Dimensional Fund Advisors LP, Mckinley Capital Management LLC Delaware, Millennium Management LLC, Commerzbank Aktiengesellschaft FI and Bank of Montreal Can. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Which major investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Brahman Capital Corp., Menora Mivtachim Holdings LTD., Harel Insurance Investments & Financial Services Ltd., Clal Insurance Enterprises Holdings Ltd, Principal Financial Group Inc., Noked Capital LTD, Los Angeles Capital Management & Equity Research Inc. and Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $17.25.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $17.54 billion and generates $18.85 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,175 (Vote Outperform)
Underperform Votes:  1,029 (Vote Underperform)
Total Votes:  2,204
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel